According to a new report published by Introspective Market Research, titled, Central Nervous System Disorders Therapeutics Market by Drug Class, Disease Type, and Distribution Channel, The Global Central Nervous System Disorders Therapeutics Market Size Was Valued at USD 129.32 Billion in 2023 and is Projected to Reach USD 226.02 Billion by 2032, Growing at a CAGR of 6.40%.
The Central Nervous System (CNS) Disorders Therapeutics Market focuses on the diagnosis, treatment, and management of neurological and psychiatric conditions such as Alzheimer’s disease, Parkinson’s disease, depression, multiple sclerosis, and epilepsy. CNS disorders affect millions globally, driving continuous research and development in targeted drug therapies and advanced treatment modalities.
The market’s growth is driven by an increasing prevalence of neurological disorders, a rapidly aging population, and continuous innovation in drug delivery and neuropharmacology. Advancements in biotechnology, coupled with improved understanding of brain function, are enabling the development of disease-modifying treatments that enhance patient outcomes. Furthermore, strategic collaborations among pharmaceutical companies and government initiatives promoting neuroscience research are bolstering the market outlook.
The Central Nervous System Disorders Therapeutics Market is segmented into Drug Class, Disease Type, and Distribution Channel.
By Drug Class, the market is categorized into (Neurodegenerative Disease Drugs, Antipsychotics, Antidepressants, Antiepileptics, and Others).
By Disease Type, the market is categorized into (Alzheimer’s Disease, Parkinson’s Disease, Epilepsy, Multiple Sclerosis, Depression, and Others).
By Distribution Channel, the market is categorized into (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies).
A major factor driving the CNS Disorders Therapeutics Market is the increasing prevalence of neurodegenerative and psychiatric disorders globally. The growing elderly population, which is more prone to Alzheimer’s and Parkinson’s diseases, coupled with lifestyle changes and stress-induced mental health conditions, is fueling demand for effective CNS drugs. Continuous R&D and the introduction of novel therapies with enhanced efficacy and fewer side effects are accelerating market expansion.
A significant market opportunity lies in emerging biologics and gene-based therapies for CNS disorders. Biotechnology advancements are enabling the development of personalized and disease-modifying treatments, especially for conditions like Alzheimer’s and multiple sclerosis. Furthermore, the integration of artificial intelligence (AI) and digital biomarkers in clinical trials is expected to improve diagnosis, treatment monitoring, and drug development efficiency, opening new growth avenues for pharmaceutical players.
Central Nervous System Disorders Therapeutics Market, Segmentation
The Central Nervous System Disorders Therapeutics Market is segmented on the basis of Drug Class, Disease Type, and Distribution Channel.
Drug Class
The Drug Class segment is further classified into Neurodegenerative Disease Drugs, Antipsychotics, Antidepressants, Antiepileptics, and Others. Among these, the Neurodegenerative Disease Drugs sub-segment accounted for the highest market share in 2024. These drugs are increasingly prescribed for Alzheimer’s and Parkinson’s diseases, supported by a growing patient base and the introduction of novel therapies aimed at slowing disease progression and improving cognitive function.
Disease Type
The Disease Type segment is further classified into Alzheimer’s Disease, Parkinson’s Disease, Epilepsy, Multiple Sclerosis, Depression, and Others. Among these, the Alzheimer’s Disease sub-segment accounted for the highest market share in 2024. The rising incidence of Alzheimer’s among the aging population and the recent approval of disease-modifying drugs are key factors driving the segment’s growth, along with continuous research in monoclonal antibody-based therapies.
Some of The Leading/Active Market Players Are-
- Biogen Inc. (USA)
- Eli Lilly and Company (USA)
- Novartis AG (Switzerland)
- Pfizer Inc. (USA)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Johnson & Johnson Services, Inc. (USA)
- AbbVie Inc. (USA)
- AstraZeneca plc (UK)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Takeda Pharmaceutical Company Ltd. (Japan)
- Otsuka Pharmaceutical Co., Ltd. (Japan)
- Merck & Co., Inc. (USA)
- Lundbeck A/S (Denmark)
- Gilead Sciences, Inc. (USA)
- other active players.
Key Industry Developments
-
In June 2024, Biogen Inc. and Eisai Co., Ltd. announced FDA approval for their Alzheimer’s treatment “Leqembi.”
The approval of Leqembi marks a significant advancement in Alzheimer’s therapy, being one of the first drugs proven to slow disease progression. This milestone reinforces the growing potential for disease-modifying therapies in neurodegenerative disorder treatment. - In October 2024, Eli Lilly received EMA approval for its new migraine prevention therapy, Emgality.
This approval strengthens Eli Lilly’s neuroscience portfolio and addresses the growing global burden of chronic migraines, representing a major step toward expanding its CNS-focused drug offerings across Europe and other markets.
Key Findings of the Study
- Neurodegenerative disease drugs dominate the global market.
- Alzheimer’s Disease segment leads in therapeutic demand.
- Rising prevalence of CNS disorders fuels steady market growth.
- Biologics and gene therapies create high-value opportunities.
- North America remains the largest regional market for CNS therapeutics.
